Clinical trials: Obese Diabetics
Impaired Glucose Tolerance, Obesity
Enhancing Fitness in Older Pre-diabetic Veterans
This study targets older adults (ages 60 and over) who are overweight (body mass index 25-40) with impaired fasting glucose (100 - 125).
- Conditions
- Impaired Glucose Tolerance, Obesity, Diabetes
- Trial name
- NCT00594399
- Testing
- Physical Activity Counseling
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- US Department of Veterans Affairs
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Insulin Resistance
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in general represent important gaps in knowledge to better understand the etiopathogenesis of T2D.
- Trial name
- NCT02597101
- Testing
- Metformin, saxagliptin, AZD9668
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nick Giannoukakis, PhD
Obese, Diabetes Mellitus, Type 2
Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects
The investigators will recruit obese subjects with pre-diabetes or type 2 diabetes for the proposed clinical study for 5 visits.
- Trial name
- NCT03991299
- Testing
- Botox 200 UNT Injection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University Medical Center
Obesity, Overweight
The Influence of Physical Activity on the Gut Microbiome of Pre-Diabetic Adults
The present study is a 100-participant randomized controlled 2-arm parallel trial that employs a metagenomic approach to examine how 8 weeks of supervised moderate-intensity treadmill walking exercise (MWE) for 30-45 min 3…
- Conditions
- Obesity, Overweight, Overweight and Obesity, PreDiabetes
- Trial name
- NCT04931836
- Testing
- Physical Activity Intervention
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Minnesota
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Obesity
Effects of Walking and Heating on Vascular Function in Diabetic Patients
The purpose of the present study is to determine the effects of increased walking and lower body heating on leg vascular function in patients with type 2 diabetes (T2D).
- Trial name
- NCT03203694
- Testing
- Walking: Intervention arm in diabetics, Walking: No intervention in diabetics, Walking: Healthy cohort as reference controls
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
This study involves research about an investigational medicine called Amlexanox. The reason for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver…
- Conditions
- Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01975935
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan
Diabetes, Obesity
Role of Methane in Glycemic Control
The purpose of this study is to determine how certain types of bacteria in the human gut may affect weight gain, and contribute to the development of diabetes.
- Trial name
- NCT01638429
- Testing
- Neomycin, Rifaximin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Obesity
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.
- Trial name
- NCT00500370
- Testing
- exenatide
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Obesity, Lifestyle-related Condition
Lifestyle Intervention in Preparation for Pregnancy (LIPP)
Studies evaluating lifestyle intervention in obese women during pregnancy have reported limited success in decreasing excessive gestational weight gain, and have failed to achieve the key outcome of breaking the obesity cycle and…
- Conditions
- Obesity, Lifestyle-related Condition, Macrosomia, Fetal
- Trial name
- NCT03146156
- Testing
- Lifestyle Intervention
- Where
- 4 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease
Amlexanox for Type 2 Diabetes and Obesity
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day.
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01842282
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Pre-diabetic State, Overweight
Feasibility of a Partnered Approach to Prevent Diabetes
The Diabetes Prevention Program (DPP) demonstrated that an intensive lifestyle intervention resulting in modest weight loss and increased physical activity can delay or prevent the development of type 2 diabetes in those at…
- Conditions
- Pre-diabetic State, Overweight, Obesity
- Trial name
- NCT00302055
- Testing
- Clinical referral to diabetes prevention lifestyle, Clinical referral to group diabetes prevention lifestyle
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Northwestern University
Type 2 Diabetes Mellitus
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.
- Trial name
- NCT00486291
- Testing
- VI-0521
- Where
- 9 sites in United States
- Volunteers
- 210 people
- Sponsor
- VIVUS LLC
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Type 2 Diabetes, Diabetes
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine whether reducing subclinical inflammation lessens insulin resistance in healthy, obese volunteers.
- Trial name
- NCT00339833
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes, Diabetes Type 2
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
The current protocol plans to enroll participants with youth-onset Type 2 Diabetes (T2D) as well as obese and lean controls from the Renal-HEIR - Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2…
- Conditions
- Type 2 Diabetes, Diabetes Type 2, Diabetic Nephropathies, Nephropathy
- Trial name
- HEIRitage (NCT05530356)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Colorado, Denver
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic